Ozilia
Commercial- Indications
- Chronic migraine, Chronic rhinitis
Company intelligence / Profile preview
Chordate Medical has developed Ozilia®, a patented neuromodulation device using Kinetic Oscillation Stimulation to treat chronic migraine and chronic rhinitis. The treatment has demonstrated efficacy in clinical studies, with CE marking obtained for both indications. It offers a drug-free alternative to traditional therapies with minimal side effects. The product is commercially available in selected European countries and Saudi Arabia, with ongoing market introduction efforts. Clinical data support its effectiveness as a non-pharmacological option that can reduce reliance on medication.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chordate Medical.